WHY US

Partner with us for Press release distribution and get best in class service, guaranteed postings on tier 1 media and maximum reach

Johnson & Johnson Medtech Partners with Qure.ai to Boost Early Detection of Lung Cancer in India

  • Thursday, May 8, 2025 6:47PM IST (1:17PM GMT)
This partnership embodies Johnson & Johnson MedTech's commitment to delivering life-saving innovations to healthcare providers
 
Mumbai, Maharashtra, India:  Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded Qure.ai, a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage.

This initiative is part of Project BreatheEZ, a broader strategic collaboration between Qure.ai and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, Qure.ai’s AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu.

In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 20251. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to detect lung cancer at an early stage, leading to delays in treatment. Thus, this collaboration between Johnson & Johnson MedTech and Qure.ai marks a significant leap forward.

By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & Qure.ai are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech’s commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care.

Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, “Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.”
 
Reference:
 
1. ICMR and NCDIR World Cancer Day 2024, Close the care gap- Addressing cancer care in India, 04th - February – 2024 https://ncdirindia.org/display/wcd.aspx.

Surgical Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what’s next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit https://www.jnj.com/medtech#surgery.


About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Private Limited is part of Johnson & Johnson MedTech.
 
Cautions Concerning Forward-Looking Statements
 
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the Strategic Partnership with Qure.ai The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K , including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Click here for Media Contact Details

Sonika Zalpuri, Avian WE, [email protected]

Submit your press release

Copyright © 2025 Business Wire India. All Rights Reserved.